Levitronix as a Short-term Salvage Treatment for Primary Graft Failure After Heart Transplantation

Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management

“…[226][227][228][229][230][231][232][233][234][235] The majority of published data describe the relatively successful use of extracorporeal membrane oxygenation (ECMO) in cases of primary graft failure. Although 30-day mortality is reduced in those who receive ECMO, in those who survive 30 days, long-term survival appears to be comparable to those who do not have primary graft failure.…”

“…226,235 Successful use of other nondurable devices, including devices from Levitronix and Abiomed, has also been reported for primary graft failure. 226,229 There are few reports specifically addressing use in the setting of AMR. [236][237][238][239] Kittleson and colleagues 239 described the use of ECMO in 32 patients with heart transplant rejection.…”

Incidence and outcome of Levitronix CentriMag support as rescue therapy for early cardiac allograft failure: a United Kingdom national study

“…Patient outcome data following the use of mechanical support for PGF is limited and most reports are from singlecentre series [5][6][7][8][9][10]. We therefore examined a national cohort of patients, who received a Levitronix CentriMag device for the treatment of PGF in UK transplant centres.…”

The Levitronix CentriMag ventricular assist device as a bridge to decision in patients with end-stage heart failure: Our single-center experience

“…The Levitronix CentriMag VAD was initially used for short-term ventricular support in post-cardiotomy failure following routine cardiac surgery, for primary graft dysfunction after heart transplantation, and for salvage as a bridge to decision in patients with severe decompensated end-stage heart failure. [1,[10][11][12][13] Figure 1. Survival of the study cohort.…”